aTyr Pharma (LIFE) Tops Q4 EPS by 35c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
aTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update
March 23, 2021 4:05 PM EDTCompleted enrollment of ATYR1923 clinical trial in patients with pulmonary sarcoidosis. Data is expected in the third quarter.
Results from ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications demonstrated favorable safety profile and signals of activity based on clinical readouts and inflammatory biomarkers.
COVID-19 findings provided first-in-patient mechanistic proof-of-concept for ATYR1923.
Company to host conference call and webcast today, March 23, at 5:00 p.m. EDT / 2:00 p.m. PDT.
SAN DIEGO, March 23, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.... More
